Reliability and Validity of the Piper Fatigue Scale in Patients with Chronic Hepatitis C Infections

2.50
Hdl Handle:
http://hdl.handle.net/10755/154716
Type:
Presentation
Title:
Reliability and Validity of the Piper Fatigue Scale in Patients with Chronic Hepatitis C Infections
Abstract:
Reliability and Validity of the Piper Fatigue Scale in Patients with Chronic Hepatitis C Infections
Conference Sponsor:Sigma Theta Tau International
Conference Year:2001
Conference Date:June, 2001
Author:Levine, Cheryl
P.I. Institution Name:University of Texas at Houston
Title:Associate Professor
Objective: To evaluate the reliability and validity of the 22 item Revised Piper Fatigue Scale (PFS) in measuring the multidimensional aspects of fatigue in a hepatitis C population undergoing treatment with Intron A and Ribavirin combination (Rebetron) therapy. Design: Psychometric evaluation. Population, Sample, Setting, Years: Three Hepatitis C clinics were utilized, including two county facilities and one academic health science center, in a large metropolitan area in the United States. As part of a larger study, PFS was completed by hepatitis C patients at four time points during Rebetron combination therapy: prior to beginning therapy, after 1 month after start of therapy, after 6 months of therapy, and after 3 months post discontinuation of therapy. Between March 1999 and February 2000, there were a total of 165 patients included in the study with 51% males and 49% females. The ethnic breakdown on the patients was 62% White, 17% Black, 15% Hispanic, and 2% Asian American. Instruments were completed by 111 patients prior to the therapy, 49 after 1 month of therapy, 60 after 6 months of therapy, and 3 at 3 months after discontinuation of therapy. Because of missed appointments, removal of the patient from treatment, or treatment prior to the beginning of the study, not every patient had a completed PFS at each time point. There were a total of 223 completed instruments with 110 subjects completing it once, 52 completing it twice, and 3 completing it three times. Concept or Variables Studied Together or Intervention and Outcome Variables: Fatigue is the most common complaint of patients with chronic active hepatitis C. In addition, fatigue is a common side effect and reason for discontinuation of Rebetron combination therapy. The PFS is a 22 item, 10 point self-report scale designed to measure current fatigue and its multidimensional aspects including behavioral/severity, affective, sensation, and cognitive/mood subscores. Mean scores on the total and the subscales have a range from 0 to 10 with higher scores indicating increased levels of fatigue. Methods: Analysis was done with SPSS using the principal axis factor analysis with varimax rotation. Findings: Four factors of fatigue were identified. The behavioral/severity and affective factors from the original Revised PFS loaded with the same items. Six items of the behavioral/severity factor loaded with values from 0.60-0.74 and 5 items of the affective factor loaded with values from 0.72-0.83. The cognitive section of the original cognitive/mood factor contained 3 items with values of 0.60-0.66. A new mood factor was supported which was a combination of 2 items from the original cognitive/mood factor and 1 from the original sensory factor with values from 0.76-0.86. The original sensory factor was not supported in this analysis. Five of the original 22 items did not load and were dropped from the adapted instrument. The four factors of behavioral/severity, affective, cognitive, and mood demonstrated reliability alphas of 0.94, 0.97, 0.96, and 0.90 respectively in the hepatitis C population. Conclusions: The adapted version of the PFS for the hepatitis C patients consists of 17 items and four factors: behavioral/severity with 6 items, affective with 5 items, cognitive with 3 items, and mood with 3 items. The Standardized alpha for the entire scale of 17 items is 0.98. Implications: Fatigue is a common symptom in patients with hepatitis C and the most common symptom in patients on Rebetron combination therapy. An instrument to accurately measure fatigue in these patients is essential in order to evaluate both the impact of this symptom in the hepatitis C population and the interventions used to modulate this symptom.
Repository Posting Date:
26-Oct-2011
Date of Publication:
Jun-2001
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleReliability and Validity of the Piper Fatigue Scale in Patients with Chronic Hepatitis C Infectionsen_GB
dc.identifier.urihttp://hdl.handle.net/10755/154716-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Reliability and Validity of the Piper Fatigue Scale in Patients with Chronic Hepatitis C Infections</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2001</td></tr><tr class="item-conference-date"><td class="label">Conference Date:</td><td class="value">June, 2001</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Levine, Cheryl</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Texas at Houston</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">clevine@son1.nur.uth.tmc.edu</td></tr><tr><td colspan="2" class="item-abstract">Objective: To evaluate the reliability and validity of the 22 item Revised Piper Fatigue Scale (PFS) in measuring the multidimensional aspects of fatigue in a hepatitis C population undergoing treatment with Intron A and Ribavirin combination (Rebetron) therapy. Design: Psychometric evaluation. Population, Sample, Setting, Years: Three Hepatitis C clinics were utilized, including two county facilities and one academic health science center, in a large metropolitan area in the United States. As part of a larger study, PFS was completed by hepatitis C patients at four time points during Rebetron combination therapy: prior to beginning therapy, after 1 month after start of therapy, after 6 months of therapy, and after 3 months post discontinuation of therapy. Between March 1999 and February 2000, there were a total of 165 patients included in the study with 51% males and 49% females. The ethnic breakdown on the patients was 62% White, 17% Black, 15% Hispanic, and 2% Asian American. Instruments were completed by 111 patients prior to the therapy, 49 after 1 month of therapy, 60 after 6 months of therapy, and 3 at 3 months after discontinuation of therapy. Because of missed appointments, removal of the patient from treatment, or treatment prior to the beginning of the study, not every patient had a completed PFS at each time point. There were a total of 223 completed instruments with 110 subjects completing it once, 52 completing it twice, and 3 completing it three times. Concept or Variables Studied Together or Intervention and Outcome Variables: Fatigue is the most common complaint of patients with chronic active hepatitis C. In addition, fatigue is a common side effect and reason for discontinuation of Rebetron combination therapy. The PFS is a 22 item, 10 point self-report scale designed to measure current fatigue and its multidimensional aspects including behavioral/severity, affective, sensation, and cognitive/mood subscores. Mean scores on the total and the subscales have a range from 0 to 10 with higher scores indicating increased levels of fatigue. Methods: Analysis was done with SPSS using the principal axis factor analysis with varimax rotation. Findings: Four factors of fatigue were identified. The behavioral/severity and affective factors from the original Revised PFS loaded with the same items. Six items of the behavioral/severity factor loaded with values from 0.60-0.74 and 5 items of the affective factor loaded with values from 0.72-0.83. The cognitive section of the original cognitive/mood factor contained 3 items with values of 0.60-0.66. A new mood factor was supported which was a combination of 2 items from the original cognitive/mood factor and 1 from the original sensory factor with values from 0.76-0.86. The original sensory factor was not supported in this analysis. Five of the original 22 items did not load and were dropped from the adapted instrument. The four factors of behavioral/severity, affective, cognitive, and mood demonstrated reliability alphas of 0.94, 0.97, 0.96, and 0.90 respectively in the hepatitis C population. Conclusions: The adapted version of the PFS for the hepatitis C patients consists of 17 items and four factors: behavioral/severity with 6 items, affective with 5 items, cognitive with 3 items, and mood with 3 items. The Standardized alpha for the entire scale of 17 items is 0.98. Implications: Fatigue is a common symptom in patients with hepatitis C and the most common symptom in patients on Rebetron combination therapy. An instrument to accurately measure fatigue in these patients is essential in order to evaluate both the impact of this symptom in the hepatitis C population and the interventions used to modulate this symptom.</td></tr></table>en_GB
dc.date.available2011-10-26T13:13:15Z-
dc.date.issued2001-06en_GB
dc.date.accessioned2011-10-26T13:13:15Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.